Senseonics Holdings CG MedTech, Diagnostics and Digital Health & Services Forum 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great. Good morning. My name is Bill Plovanic. I'm a Senior Medical Device Analyst here. Welcome to the Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum. With us next is Tim Goodnow. Tim is President and CEO of Senseonics. With that, I'll hand it over to Tim.
Great. Thank you, Bill. Appreciate the opportunity to speak today. Senseonics is a technology company in the MedTech space, obviously in continuous glucose monitoring. Many of you are familiar. It is a significant space. It's evolved over the last 15 years with a couple of large players. Senseonics has a new and differentiated technology. We're happy to report some good success here of late, as we transition the organization over the last year or so. Technology is very different. The CGMs that are out there today have evolved to somewhat similar. They're transcutaneous devices that measure glucose every five minutes. Senseonics' approach is different. We've gone for a long-term solution, so we have a sensor that's inserted in a doctor's office just under the skin, and it stays resident for an entire year.
Bringing folks kind of a freedom and ease of use, which is different from the replaceable products that happens about on a two-week basis. We've transitioned the business pretty significantly. We had a partnership with Ascensia Diabetes Care, a traditional strip and meter business, in 2025 that we transitioned, started January 1st of 2026. So, results that we're now showing are for the standalone business, which has had some encouraging results, not only from a control and a destiny perspective, but also from a financial consolidation. We're very, very focused on the space. As you can imagine, the diabetes glucose market is huge, $15 billion this year. But for us, it's really about the commercial growth, which we've shown good success.
We've announced essentially a doubling of sales this year, and we're on track to approach that for 2027, as well as an innovation pipeline that's highly differentiated and leverages the full implant capability of the sensor. Strong commercial momentum. We announced the other night 140% growth year-over-year, as well as strong growth quarter-over-quarter. As I said, with a quite differentiated roadmap. If one looks at the market, growth has been CAGR of high double digits. We anticipate that we'll be about $15 billion this year. There's 11 million people on CGM, and that's evolved pretty significantly over the last few years. As I said, we are the long-term sensor. The positive, of course, is that long-term duration. Put the sensor in and forget about it. The negative is you do need to go to the doctor's office to do the procedure.
We've worked hard to facilitate that as much as we can and give people that 365 days of freedom. As a result of it being obviously a long-term implant, there's very, very low threshold for failures. We've designed the product to be very, very stable. It is very accurate. There are three what's designated as iCGMs on the market. Those are the sensors that can be interchangeable with the pump connectivity, and Eversense is one of the three, along with the Dexcom and the Abbott product. That's really allowed us to not only brand the product, but develop a well-earned reputation for a high-quality product. One of that aspects is, as we'll see, is to get away from some of the short-term sensor replacements that happen with those transcutaneous sensors.
Because we don't have to have a skin adhesive that locks the sensor in place for long term, we've really minimized the skin irritations, which is one of the points of frustrations and one of the reasons that we are able to move the product that we're able to do it. Also, especially important in the AID or the automated insulin delivery, is we've eliminated the compression lows, which is a false low that happens when you roll over and sleep on one of the transcutaneous sensors. In a combined pump, it'll actually give you an alarm for hypoglycemia, but it also turns the pump off. It's a pretty significant nuisance for the real world living with a integrated product. What we are noting is that the vast majority, 90% of our patients, are all switching from one of the other CGMs. Why is that? It really comes from the sensor survivability.
If you look at the competing transcutaneous products, the reality is about 15%-20% of those sensors don't go to the full 15 days. That creates a hassle of having to replace the product. If you're at the office and it comes off or it terminates, it's really a pain in the neck to do it. When a lot of people get frustrated with it is when they'll come and look for another alternative, and we offer a good solution to that. As I said, about 90% are coming from one of the other products. It's a pretty equal split between the Dexcom G7 or the Abbott Libre 3. 10% are new. Those are folks that are looking for a solution and have identified the long-term implant as being something that can work for them.
Importantly, as I mentioned, is the AID integration for people with type 1 diabetes that are pumping. There's a couple million folks that actually pump, and tying it to a CGM gives that autonomous or that ability, like the thermostat on your wall, to control the temperature and keep it in range. We do the same thing. You give insulin when you're high blood sugar, and you stop that insulin delivery when you're low. We partnered with two. We've had a great year with twiist Sequel Med Tech. Delivered a new pump at the beginning of the year that we partnered with, and it's really been strong performance for us. The acceptance of the product was encouraging and higher than we had anticipated. We're also excited to announce that we have also partnered with Beta Bionics, and we'll actually be launching that product in about the next week.
We will be pretty significantly expanding the capability of AID integration. I said this is predominantly type 1 diabetes. There is a little bit of pumping in type 2, but for people that have the autoimmune disease, this is a great solution, and Eversense has worked out extremely well for them. That is demonstrated by here are our early results. If one looks, putting people on Eversense, and this is real-world experience, you will see that if you put a population on Eversense, the bottom line is they will increase their time in range to about 66%. That is normal glycemic levels in about two-thirds of the patients. When you put them on an AID system, specifically with the Sequel pump and Eversense, you see that jumps to 76%. That is actually the highest published results of time in range of any of the combined integrated systems. We are really encouraged. That comes from the compliance of a one-year sensor.
As I said, it does not come off every week, as well as the Loop algorithm that is part of the Sequel product is highly advanced and pretty differentiated. I think that will be the next area that people will start to peel the onion skin back on and take a look, is in regards to the differences between the different treatment algorithms that are out there. We are real excited to have that relationship. Also excited about the opportunity to work with Beta Bionics, which is also an easy-to-implement pump with their algorithm choice. You just enter the weight and actually can get patients started right away.
The Loop algorithm is really for an advanced user that is looking for a lot of flexibility, a lot of capability, whereas the Beta Bionics is really one that you can put on, especially folks that are newly diagnosed, and help them come up to speed. We are excited to be able to cover both of those aspects with Eversense now. As I said, this is the growth trajectory. We have really expanded. The earlier data was with a partnership, so we shared the revenue. In 2025, we ended that, and as I said, we have been able to grow at essentially 100% or very near 100% here this year, both in revenue, and that is driven by the new patient growth. Those are the folks that I described that are coming over from the other products. We focused on significant increase in the number of people that are doing the insertion.
I will talk about our Eon Care network, as well as the prescribers have grown significantly as well. This is all a result of the focus work that we have done with our high-capable commercial organization. How have we done that? For us, it is really, as you can imagine, as the third real entrant into the standalone CGM space, it has been important for us to get a share of voice. We focus very significantly on awareness and investment in digital marketing, which allows us to be very, very directed, and that has resulted in now about 60% of our new patients are actually coming from DTC. We will put out predominantly on Meta, solicit interest, and they will come to us, and we have an inside sales team that will do the detailing, the education, the insurance adjudication, and move people towards it.
Access has been another area, of course, that we focused on. Obviously, you want to be able to make sure you've got all the reimbursement in place. We've done a very good job with that, not only with commercial pay, but also through Medicare reimbursement. Also this Eon network that I'll talk about. Eon is our subsidiary. We have about 100 nurses that do the insertion for us, and our team has done a great job at not only expanding the breadth of the offices that we call on. There's also another 43 reps that call on the large diabetology clinics, endocrinology. We've gone deeper into the clinics, but also gone to more clinics as well. Once you earn the patient, of course, being able to retain them and have them stay with you for sensor after sensor is important as well.
We've done a very good job at people staying on the product. Once they have it for an entire year, they get very comfortable with it becomes part of their life, and they're renewing at an exciting pace for us. That's the razor blade part of the business model as well. How do we commercialize? As I said, about 60% of our patients are coming from the DTC channel, so they're coming into us based on that awareness that we're creating, all web-based at this point, social media. About 40% are coming from the HCP or the healthcare professional channel. Those are the sales reps that are going out and calling on the doctors, and then they're recommending the product for their patients. That's a traditional approach. They'll make a recommendation. There's a pretty high conversion rate when the doctor recommends the product.
On the DTC channel, it's the typical solicitation that you'd expect. Somebody will submit a lead, we'll follow up on it. We do need to filter those for what we call workable leads. That generally means people that are eligible for reimbursement, right? There's a lot of people today that have diabetes that are not yet on insulin, and if you're not on insulin, you're typically not reimbursed for the product. So it would have to be a cash pay. So we'll work with them, filter for that, understand what exactly type of insurance they have, where they're geolocated, how close they are to an insertion site, and so forth, and then that will convert them to an opportunity.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
